DSIP: Delta-Wave Sleep Claims and the Evidence Behind Them
A nonapeptide originally isolated from rabbit brain, studied for its role in inducing delta-wave (deep) sleep.
What is DSIP (Delta Sleep-Inducing Peptide)?
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first isolated from the brains of rabbits during studies of sleep physiology. It's studied for effects on delta-wave (deep, slow-wave) sleep induction, stress-response modulation, and circadian regulation. Its native human plasma half-life is extremely short — a matter of minutes — and no formal clinical dosing protocol has been established. It's sold only as a research compound.
Quick facts
- Molecular Formula
- C35H48N10O15
- Molecular Weight
- 848.8 g/mol
- CAS Number
- 62568-57-4
- Sequence
- Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
- Half-Life
- ~7-8 minutes (human plasma)
- Class
- Nonapeptide, sleep-regulatory neuropeptide
- Brand Names
- No trademarked brand — sold as a research compound
- Legal Status
- Not FDA-approved for human use — research use only (RUO)
- Category
- Sleep & Recovery
- Storage
- Store the lyophilized vial refrigerated (2-8°C) or at -20°C, away from light. Once reconstituted, keep refrigerated at 2-8°C and use promptly.
Dosing at a glance
5mg vial + 2mL bacteriostatic water = 2500mcg/mL. Run the numbers in the reconstitution calculator.
Doses shown are those reported in published research, not a recommendation.
DSIP (Delta Sleep-Inducing Peptide) Mechanism of Action
Delta-Wave Sleep Research Origin
DSIP was first identified in the 1970s in studies where blood from sleep-deprived rabbits was found to induce delta-wave (deep, slow-wave) sleep patterns when transferred to other animals. The nonapeptide responsible was isolated and named accordingly. Its exact receptor mechanism in humans remains incompletely characterized compared to modern, well-mapped GPCR-targeting peptides.
Stress and Circadian Modulation
Beyond its namesake sleep effect, DSIP has been studied for roles in stress-response buffering and circadian regulation, with some research suggesting interaction with the hypothalamic-pituitary-adrenal (HPA) axis. Most of this evidence comes from older animal studies rather than modern, well-controlled human trials.
DSIP (Delta Sleep-Inducing Peptide) Dosage and Protocols
Pre-Bed Protocol
Vendor/research-typical dosing is 100–300mcg subcutaneous, administered shortly before bed. No formal clinical dose-finding study exists for general research use — this range reflects informal research-community convention only.
DSIP (Delta Sleep-Inducing Peptide) Side Effects and Safety
Limited Safety Data
No modern, comprehensive human safety data exists for DSIP. Older studies reported it as generally well tolerated at studied doses, but formal adverse-event surveillance at scale has never been conducted. Active psychiatric conditions and pregnancy are treated as precautionary contraindications.
DSIP (Delta Sleep-Inducing Peptide) Research Evidence
Dated, Limited Human Data
Much of the foundational DSIP research dates to the 1970s-1990s, predating modern clinical trial standards. Some small human studies explored effects on sleep architecture and stress hormones, but the evidence base is thin and outdated by current standards, with no large modern randomized controlled trial.
Regulatory and Legal Status
DSIP has no FDA-approved indication and is not approved for human consumption. It is sold exclusively as a research-grade compound (RUO). Researchers and users should verify the legal status of DSIP in their jurisdiction prior to purchase or use.
DSIP (Delta Sleep-Inducing Peptide) Stacking and Combinations
DSIP + Epithalon
A common research pairing for sleep and circadian-rhythm research, combining DSIP's studied delta-sleep effects with epithalon's pineal-gland/melatonin-pathway research angle. No formal trial data exists for this combination.
DSIP (Delta Sleep-Inducing Peptide) Pharmacokinetics
Extremely Short Half-Life
DSIP has a documented human plasma half-life of approximately 7-8 minutes. In vitro stability is even shorter — about 15 minutes — due to a specific aminopeptidase-like enzyme that rapidly degrades it. This very short half-life is part of why it's dosed shortly before the sleep window it's intended to influence.
More on DSIP (Delta Sleep-Inducing Peptide) pharmacokinetics
Contraindications
- pregnancy
- active psychiatric conditions without physician oversight
Frequently asked questions
What is a typical DSIP (Delta Sleep-Inducing Peptide) dose?
Published research protocols report 100–300 mcg, before bed. This is the range described in the literature, not a recommendation.
What is the half-life of DSIP (Delta Sleep-Inducing Peptide)?
~7-8 minutes in human plasma.
Is DSIP (Delta Sleep-Inducing Peptide) backed by strong evidence?
DSIP (Delta Sleep-Inducing Peptide) carries a REGEN research grade of D. REGEN Research Tier D — a handful of small human studies from the 1970s and 80s, then effectively abandoned.
How is DSIP (Delta Sleep-Inducing Peptide) administered?
Routes reported in the literature: subcutaneous.
Who should avoid DSIP (Delta Sleep-Inducing Peptide)?
Contraindications noted in the literature include pregnancy, active psychiatric conditions without physician oversight.
References
- Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients: A Double-Blind Study · Schneider-Helmert D, Schoenenberger GA · 1992